Cell-free DNA in the blood as a solid tumor biomarker-A critical appraisal of the literature

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1611-1624

  Jung, Klaus ^a,b   Fleischhacker, Michael ^a   Rabien, Anja ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

Circulating cell free DNA; Genometastasis hypothesis; Methylation marker; Microsatellites; Mutations; Solid cancer

Indexed keywords

CELL DNA; MESSENGER RNA; MICRORNA; MICROSATELLITE DNA; MITOCHONDRIAL DNA; TUMOR MARKER; UNTRANSLATED RNA;

ANALYTIC METHOD; CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA METHYLATION; DNA STRAND; GENE MUTATION; HUMAN; MICROSATELLITE MARKER; NONHUMAN; ONCOGENE; PATIENT MONITORING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

BLOOD SPECIMEN COLLECTION; DNA, NEOPLASM; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; METHODS; NEOPLASMS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL; UNCERTAINTY;

EID: 77956467360     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.07.032     Document Type: Review

References (241)

1. Mandel P., Metais P. Les acides nucleiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948, 142:241-243.
2. Bendich A., Wilczok T., Borenfreund E. Circulating DNA as a possible factor in oncogenesis. Science 1965, 148:374-376.
3. Tan E.M., Schur P.H., Carr R.I., Kunkel H.G. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966, 45:1732-1740.
4. Koffler D., Agnello V., Winchester R., Kunkel H.G. The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 1973, 52:198-204.
5. Perlin E., Moquin R.B. Serum DNA levels in patients with malignant disease. Am J Clin Pathol 1972, 58:601-602.
6. Steinman C.R. Free DNA in serum and plasma from normal adults. J Clin Invest 1975, 56:512-515.
7. Kamm R.C., Smith A.G. Nucleic acid concentrations in normal human plasma. Clin Chem 1972, 18:519-522.
8. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
9. Stroun M., Anker P., Maurice P., Lyautey J., Lederrey C., Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989, 46:318-322.
10. Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederrey C., Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994, 86:774-779.
11. Sorenson G.D., Pribish D.M., Valone F.H., Memoli V.A., Bzik D.J., Yao S.L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev 1994, 3:67-71.
12. Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996, 2:1035-1037.
13. Chen X.Q., Stroun M., Magnenat J.L., et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996, 2:1033-1035.
14. Anker P., Lefort F., Vasioukhin V., et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997, 112:1114-1120.
15. Chiang P.W., Beer D.G., Wei W.L., Orringer M.B., Kurnit D.M. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res 1999, 5:1381-1386.
16. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999, 59:67-70.
17. Lo Y.M., Corbetta N., Chamberlain P.F., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350:485-487.
18. Lo Y.M., Tein M.S., Pang C.C., Yeung C.K., Tong K.L., Hjelm N.M. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 1998, 351:1329-1330.
19. Rainer T.H., Wong L.K., Lam W., et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem 2003, 49:562-569.
20. Chang C.P., Chia R.H., Wu T.L., Tsao K.C., Sun C.F., Wu J.T. Elevated cell-free serum DNA detected in patients with myocardial infarction. Clin Chim Acta 2003, 327:95-101.
21. Hu L., Chen G., Yu H., Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 2010, 4:423-432.
22. Cabral R.E., Caldeira-de-Araujo A., Cabral-Neto J.B., Costa Carvalho M.D. Analysis of GSTM1 and GSTT1 polymorphisms in circulating plasma DNA of lung cancer patients. Mol Cell Biochem 2010, 338:263-269.
23. Arnalich F., Menendez M., Lagos V., et al. Prognostic value of cell-free plasma DNA in patients with cardiac arrest outside the hospital: an observational cohort study. Crit Care 2010, 14:R47.
24. Liggett T., Melnikov A., Yi Q.L., et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010, 116:1674-1680.
25. Kamat A.A., Baldwin M., Urbauer D., et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer 2010, 116:1918-1925.
26. Garcia-Olmo D.C., Dominguez C., Garcia-Arranz M., et al. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res 2010, 70:560-567.
27. Circulating nucleic acids in plasma or serum I. Ann N Y Acad Sci 2000, vol. 906. New York Academy of Sciences, New York. P. Anker, M. Stroun (Eds.).
28. Circulating nucleic acids in plasma or serum II. Ann N Y Acad Sci 2001, vol. 945. New York Academy of Sciences, New York. Y.M.D. Lo, R.W.K. Chiu, P.J. Johnson (Eds.).
29. Hoon D.S.B., Taback B. Circulating nucleic acids in plasma or serum III. Ann N Y Acad Sci 2004, vol. 1022. New York Academy of Sciences, New York.
30. Circulating nucleic acids in plasma or serum IV. Ann N Y Acad Sci 2006, vol. 1075. New York Academy of Sciences, New York. R. Swaminathan, A. Butt, P. Gahan (Eds.).
31. Circulating nucleic acids in plasma or serum V. Ann N Y Acad Sci 2008, vol. 1137. New York Academy of Sciences, New York. P.B. Gahan, R. Swaminathan (Eds.).
32. Bremnes R.M., Sirera R., Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer 2005, 49:1-12.
33. van der Vaart M., Pretorius P.J. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?. Clin Biochem 2010, 43:26-36.
34. Vlassov V.V., Laktionov P.P., Rykova E.Y. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010, 10:142-165.
35. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007, 635:105-117.
36. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007, 1775:181-232.
37. Jahr S., Hentze H., Englisch S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
38. Stroun M., Anker P., Lyautey J., Lederrey C., Maurice P.A. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987, 23:707-712.
39. Skvortsova T.E., Rykova E.Y., Tamkovich S.N., et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006, 94:1492-1495.
40. Suzuki N., Kamataki A., Yamaki J., Homma Y. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 2008, 387:55-58.
41. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., Anker P. About the possible origin and mechanism of circulating DNA: apoptosis and active DNA release. Clin Chim Acta 2001, 313:139-142.
42. Ziegler A., Zangemeister-Wittke U., Stahel R.A. Circulating DNA: a new diagnostic gold mine?. Cancer Treat Rev 2002, 28:255-271.
43. Stroun M., Lyautey J., Lederrey C., Mulcahy H.E., Anker P. Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells?. Ann NY Acad Sci 2001, 945:258-264.
44. Gahan P.B., Anker P., Stroun M. Metabolic DNA as the origin of spontaneously released DNA?. Ann NY Acad Sci 2008, 1137:7-17.
45. Gahan P.B. Circulating DNA: intracellular and intraorgan messenger?. Ann NY Acad Sci 2006, 1075:21-33.
46. Stroun M., Maurice P., Vasioukhin V., et al. The origin and mechanism of circulating DNA. Ann NY Acad Sci 2000, 906:161-168.
47. Li C.N., Hsu H.L., Wu T.L., Tsao K.C., Sun C.F., Wu J.T. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal 2003, 17:103-107.
48. Wu T.L., Zhang D., Chia J.H., Tsao K.H., Sun C.F., Wu J.T. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 2002, 321:77-87.
49. Choi J.J., Reich C.F., Pisetsky D.S. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 2005, 115:55-62.
50. Holdenrieder S., Stieber P., Chan L.Y., et al. Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem 2005, 51:1544-1546.
51. Diehl F., Li M., Dressman D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005, 102:16368-16373.
52. Schwarzenbach H., Alix-Panabieres C., Muller I., et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009, 15:1032-1038.
53. Garcia-Olmo D.C., Samos J., Picazo M.G., Asensio A.I., Toboso I., Garcia-Olmo D. Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett 2008, 272:133-140.
54. Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
55. Lo Y.M., Zhang J., Leung T.N., Lau T.K., Chang A.M., Hjelm N.M. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999, 64:218-224.
56. Minchin R.F., Carpenter D., Orr R.J. Polyinosinic acid and polycationic liposomes attenuate the hepatic clearance of circulating plasmid DNA. J Pharmacol Exp Ther 2001, 296:1006-1012.
57. Tamkovich S.N., Cherepanova A.V., Kolesnikova E.V., et al. Circulating DNA and DNase activity in human blood. Ann NY Acad Sci 2006, 1075:191-196.
58. Korabecna M., Opatrna S., Wirth J., et al. Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease. Ann NY Acad Sci 2008, 1137:296-301.
59. Puszyk W.M., Crea F., Old R.W. Unequal representation of different unique genomic DNA sequences in the cell-free plasma DNA of individual donors. Clin Biochem 2009, 42:736-738.
60. Sorenson G.D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000, 6:2129-2137.
61. Cherepanova A.V., Tamkovich S.N., Bryzgunova O.E., Vlassov V.V., Laktionov P.P. Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Ann NY Acad Sci 2008, 1137:218-221.
62. Garcia-Olmo D., Garcia-Olmo D.C. Functionality of circulating DNA: the hypothesis of genometastasis. Ann NY Acad Sci 2001, 945:265-275.
63. Garcia-Olmo D.C., Ruiz-Piqueras R., Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 2004, 19:575-583.
64. Bergsmedh A., Szeles A., Henriksson M., et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 2001, 98:6407-6411.
65. Skvortsova T.E., Vlassov V.V., Laktionov P.P. Binding and penetration of methylated DNA into primary and transformed human cells. Ann NY Acad Sci 2008, 1137:36-40.
66. Chen Z., Fadiel A., Naftolin F., Eichenbaum K.D., Xia Y. Circulation DNA: biological implications for cancer metastasis and immunology. Med Hypotheses 2005, 65:956-961.
67. Bennett R.M., Gabor G.T., Merritt M.M. DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. J Clin Invest 1985, 76:2182-2190.
68. Jen J., Wu L., Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann NY Acad Sci 2000, 906:8-12.
69. Lee T.H., Montalvo L., Chrebtow V., Busch M.P. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001, 41:276-282.
70. Chiu R.W., Poon L.L., Lau T.K., Leung T.N., Wong E.M., Lo Y.M. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 2001, 47:1607-1613.
71. Lui Y.Y., Chik K.W., Lo Y.M. Does centrifugation cause the ex vivo release of DNA from blood cells?. Clin Chem 2002, 48:2074-2076.
72. Thijssen M.A., Swinkels D.W., Ruers T.J., de Kok J.B. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 2002, 22:421-425.
73. Lui Y.Y., Chik K.W., Chiu R.W., Ho C.Y., Lam C.W., Lo Y.M. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002, 48:421-427.
74. Jung M., Klotzek S., Lewandowski M., Fleischhacker M., Jung K. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 2003, 49:1028-1029.
75. Xue X., Teare M.D., Holen I., Zhu Y.M., Woll P.J. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta 2009, 404:100-104.
76. Herrera L.J., Raja S., Gooding W.E., et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005, 51:113-118.
77. Sozzi G., Roz L., Conte D., et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 2005, 97:1848-1850.
78. Jung K., Stephan C., Lewandowski M., et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004, 205:173-180.
79. de Kok J.B., Hendriks J.C., van Solinge W.W., Willems H.L., Mensink E.J., Swinkels D.W. Use of real-time quantitative PCR to compare DNA isolation methods. Clin Chem 1998, 44:2201-2204.
80. Chun F.K., Muller I., Lange I., et al. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006, 98:544-548.
81. Stemmer C., Beau-Faller M., Pencreac'h E., et al. Use of magnetic beads for plasma cell-free DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics. Clin Chem 2003, 49:1953-1955.
82. Schmidt B., Weickmann S., Witt C., Fleischhacker M. Improved method for isolating cell-free DNA. Clin Chem 2005, 51:1561-1563.
83. Jorgez C.J., Dang D.D., Simpson J.L., Lewis D.E., Bischoff F.Z. Quantity versus quality: optimal methods for cell-free DNA isolation from plasma of pregnant women. Genet Med 2006, 8:615-619.
84. Fong S.L., Zhang J.T., Lim C.K., Eu K.W., Liu Y. Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients. Clin Chem 2009, 55:587-589.
85. Liu K.J., Brock M.V., Shih I., Wang T.H. Decoding circulating nucleic acids in human serum using microfluidic single molecule spectroscopy. J Am Chem Soc 2010, 132:5793-5798.
86. Wang M., Block T.M., Steel L., Brenner D.E., Su Y.H. Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 2004, 50:211-213.
87. Ellinger J., Bastian P.J., Ellinger N., et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett 2008, 264:274-280.
88. Vitzthum F., Geiger G., Bisswanger H., Brunner H., Bernhagen J. A quantitative fluorescence-based microplate assay for the determination of double-stranded DNA using SYBR Green I and a standard ultraviolet transilluminator gel imaging system. Anal Biochem 1999, 276:59-64.
89. Horlitz M., Lucas A., Sprenger-Haussels M. Optimized quantification of fragmented, free circulating DNA in human blood plasma using a calibrated duplex real-time PCR. PLoS ONE 2009, 4:e7207.
90. deVos T., Tetzner R., Model F., et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009, 55:1337-1346.
91. Szpechcinski A., Struniawska R., Zaleska J., et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol 2008, 59(Suppl 6):675-681.
92. Altimari A., Grigioni A.D., Benedettini E., et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 2008, 129:756-762.
93. Boddy J.L., Gal S., Malone P.R., Harris A.L., Wainscoat J.S. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 2005, 11:1394-1399.
94. Schwarzenbach H., Chun F.K., Lange I., et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer 2007, 120:1465-1471.
95. Gormally E., Hainaut P., Caboux E., et al. Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 2004, 111:746-749.
96. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003, 49:1-6.
97. Fiegl H., Millinger S., Mueller-Holzner E., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005, 65:1141-1145.
98. Chang H.W., Lee S.M., Goodman S.N., et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 2002, 94:1697-1703.
99. Sozzi G., Conte D., Leon M., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003, 21:3902-3908.
100. Paci M., Maramotti S., Bellesia E., et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009, 64:92-97.
101. Fournie G.J., Courtin J.P., Laval F., et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995, 91:221-227.
102. Beau-Faller M., Gaub M.P., Schneider A., et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 2003, 105:361-370.
103. Bastian P.J., Palapattu G.S., Yegnasubramanian S., et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 2007, 13:5361-5367.
104. Papadopoulou E., Davilas E., Sotiriou V., et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann NY Acad Sci 2006, 1075:235-243.
105. Kohler C., Radpour R., Barekati Z., et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 2009, 8:105.
106. Zhong X.Y., Ladewig A., Schmid S., Wight E., Hahn S., Holzgreve W. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 2007, 276:327-331.
107. Umetani N., Giuliano A.E., Hiramatsu S.H., et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006, 24:4270-4276.
108. Catarino R., Ferreira M.M., Rodrigues H., et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008, 27:415-421.
109. Schwarzenbach H., Muller V., Stahmann N., Pantel K. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann NY Acad Sci 2004, 1022:25-32.
110. Banki F., Mason R.J., Oh D., et al. Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. Arch Surg 2007, 142:533-538.
111. Atamaniuk J., Vidotto C., Tschan H., Bachl N., Stuhlmeier K.M., Muller M.M. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem 2004, 50:1668-1670.
112. Fournie G.J., Martres F., Pourrat J.P., Alary C., Rumeau M. Plasma DNA as cell death marker in elderly patients. Gerontology 1993, 39:215-221.
113. Rainer T.H., Lam N.Y. Circulating nucleic acids and critical illness. Ann NY Acad Sci 2006, 1075:271-277.
114. Agalou S., Butt A.N., Chowienczyk P., Swaminathan R. Hypertension and circulating mRNA for 11beta-hydroxysteroid dehydrogenase type II. Ann NY Acad Sci 2008, 1137:290-295.
115. Uzuelli J.A., Dias-Junior C.A., Izidoro-Toledo T.C., Gerlach R.F., Tanus-Santos J.E. Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism. Clin Chim Acta 2009, 409:112-116.
116. Zhang R., Shao F., Wu X., Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 2010, 69:225-231.
117. Schmidt B., Weickmann S., Witt C., Fleischhacker M. Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann NY Acad Sci 2008, 1137:207-213.
118. Belinsky S.A., Klinge D.M., Dekker J.D., et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005, 11:6505-6511.
119. Gal S., Fidler C., Lo Y.M., et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004, 90:1211-1215.
120. Zanetti-Dallenbach R.A., Schmid S., Wight E., et al. Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers 2007, 22:95-99.
121. Sunami E., Vu A.T., Nguyen S.L., Giuliano A.E., Hoon D.S. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann NY Acad Sci 2008, 1137:171-174.
122. Huang Z.H., Li L.H., Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 2006, 243:64-70.
123. Ellinger J., Wittkamp V., Albers P., et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol 2009, 181:363-371.
124. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
125. Silva J.M., Silva J., Sanchez A., et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 2002, 8:3761-3766.
126. Tokuhisa Y., Iizuka N., Sakaida I., et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007, 97:1399-1403.
127. Ren N., Ye Q.H., Qin L.X., Zhang B.H., Liu Y.K., Tang Z.Y. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol 2006, 12:3911-3914.
128. Ren N., Qin L.X., Tu H., Liu Y.K., Zhang B.H., Tang Z.Y. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006, 132:399-407.
129. Yoon K.A., Park S., Lee S.H., Kim J.H., Lee J.S. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 2009, 11:182-185.
130. Gautschi O., Bigosch C., Huegli B., et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004, 22:4157-4164.
131. van der Drift M.A., Hol B.E., Klaassen C.H., et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2010, 68:283-287.
132. Ludovini V., Pistola L., Gregorc V., et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol 2008, 3:365-373.
133. Kumar S., Guleria R., Singh V., Bharti A.C., Mohan A., Das B.C. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer Februray 22 2010, Epub ahead of print. 10.1016/j.lungcan.2010.01.021.
134. Sozzi G., Conte D., Mariani L., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001, 61:4675-4678.
135. Kumar S., Guleria R., Singh V., Bharti A.C., Mohan A., Das B.C. Plasma DNA level in predicting therapeutic efficacy in advanced non-small cell lung cancer. Eur Respir J February 25 2010, Epub ahead of print. 10.1183/09031936.00187909.
136. Kamat A.A., Bischoff F.Z., Dang D., et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 2006, 5:1357-1362.
137. Rago C., Huso D.L., Diehl F., et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 2007, 67:9364-9370.
138. Frattini M., Gallino G., Signoroni S., et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 2008, 263:170-181.
139. Banki F., Yacoub W.N., Hagen J.A., et al. Plasma DNA is more reliable than carcinoembryonic antigen for diagnosis of recurrent esophageal cancer. J Am Coll Surg 2008, 207:30-35.
140. Perego R.A., Corizzato M., Brambilla P., et al. Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. Eur J Cancer 2008, 44:1039-1047.
141. Zitt M., Muller H.M., Rochel M., et al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers 2008, 25:159-165.
142. Kamat A.A., Kim T.J., Landen C.N., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007, 67:281-288.
143. Capizzi E., Gabusi E., Grigioni A.D., et al. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Diagn Mol Pathol 2008, 17:34-38.
144. Deligezer U., Eralp Y., Akisik E.E., et al. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med 2008, 46:311-317.
145. Cheng C., Omura-Minamisawa M., Kang Y., Hara T., Koike I., Inoue T. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci 2009, 100:303-309.
146. Giacona M.B., Ruben G.C., Iczkowski K.A., Roos T.B., Porter D.M., Sorenson G.D. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998, 17:89-97.
147. Wang B.G., Huang H.Y., Chen Y.C., et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003, 63:3966-3968.
148. Gang F., Guorong L., An Z., Anne G.P., Christian G., Jacques T. Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology 2010, 75:262-265.
149. Holdenrieder S., Burges A., Reich O., Spelsberg F.W., Stieber P. DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann NY Acad Sci 2008, 1137:162-170.
150. Chan K.C., Leung S.F., Yeung S.W., Chan A.T., Lo Y.M. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res 2008, 14:4141-4145.
151. Ellinger J., Bastian P.J., Haan K.I., et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 2008, 122:138-143.
152. Umetani N., Kim J., Hiramatsu S., et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006, 52:1062-1069.
153. Jiang W.W., Zahurak M., Goldenberg D., et al. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 2006, 119:2673-2676.
154. Hanley R., Rieger-Christ K.M., Canes D., et al. DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res 2006, 12:4569-4574.
155. Tomita H., Ichikawa D., Ikoma D., et al. Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 2007, 27:2737-2741.
156. Boddy J.L., Gal S., Malone P.R., Shaida N., Wainscoat J.S., Harris A.L. The role of cell-free DNA size distribution in the management of prostate cancer. Oncol Res 2006, 16:35-41.
157. Gormally E., Vineis P., Matullo G., et al. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 2006, 66:6871-6876.
158. Shao Z.M., Wu J., Shen Z.Z., Nguyen M. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res 2001, 7:2222-2227.
159. Silva J.M., Garcia J.M., Dominguez G., et al. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002, 9:71-76.
160. Ito T., Kaneko K., Makino R., et al. Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma. Oncol Rep 2003, 10:1937-1942.
161. Lecomte T., Berger A., Zinzindohoue F., et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002, 100:542-548.
162. Lindforss U., Zetterquist H., Papadogiannakis N., Olivecrona H. Persistence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 2005, 25:657-661.
163. Gonzalez R., Silva J.M., Sanchez A., et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol 2000, 11:1097-1104.
164. Kimura T., Holland W.S., Kawaguchi T., et al. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann NY Acad Sci 2004, 1022:55-60.
165. Szymanska K., Chen J.G., Cui Y., et al. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomark Prev 2009, 18:1638-1643.
166. Jackson P.E., Kuang S.Y., Wang J.B., et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis 2003, 24:1657-1663.
167. Däbritz J., Hänfler J., Preston R., Stieler J., Oettle H. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer 2005, 92:405-412.
168. Marchese R., Muleti A., Pasqualetti P., et al. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 2006, 32:171-177.
169. Jiao L., Zhu J., Hassan M.M., Evans D.B., Abbruzzese J.L., Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 2007, 34:55-62.
170. Däbritz J., Preston R., Hänfler J., Oettle H. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas 2009, 38:534-541.
171. Castells A., Puig P., Mora J., et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999, 17:578-584.
172. Magistrelli P., Neri M., Granone P., Cesario A., Paleari L., Russo P. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value. Pancreas 2008, 37:101-102.
173. Dobrzycka B., Terlikowski S.J., Mazurek A., et al. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer 2010, 127:612-621.
174. Otsuka J., Okuda T., Sekizawa A., et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer 2004, 14:459-464.
175. Chen Z., Feng J., Buzin C.H., et al. Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS ONE 2009, 4:e7220.
176. Huang X.H., Sun L.H., Lu D.D., et al. Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China. World J Gastroenterol 2003, 9:692-695.
177. Hsieh J.S., Lin S.R., Chang M.Y., et al. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 2005, 71:336-343.
178. Daniotti M., Vallacchi V., Rivoltini L., et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 2007, 120:2439-2444.
179. Chuang T.C., Chuang A.Y., Poeta L., Koch W.M., Califano J.A., Tufano R.P. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 2010, 32:229-234.
180. Mack P.C., Holland W.S., Burich R.A., et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009, 4:1466-1472.
181. Bai H., Mao L., Wang H.S., et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27:2653-2659.
182. Kuang Y., Rogers A., Yeap B.Y., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15:2630-2636.
183. Park K.U., Lee H.E., Park D.J., et al. MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med 2009, 47:530-536.
184. Gotoh T., Hosoi H., Iehara T., et al. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol 2005, 23:5205-5210.
185. Ramirez J.L., Sarries C., de Castro P.L., et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003, 193:207-216.
186. Camps C., Sirera R., Bremnes R., et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?. Lung Cancer 2005, 50:339-346.
187. Board R.E., Knight L., Greystoke A., et al. DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark Insights 2007, 2:307-319.
188. Kristensen L.S., Hansen L.L. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 2009, 55:1471-1483.
189. Kagan J., Srivastava S., Barker P.E., Belinsky S.A., Cairns P. Towards clinical application of methylated DNA sequences as cancer biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res 2007, 67:4545-4549.
190. Mirza S., Sharma G., Prasad C.P., et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007, 81:280-287.
191. Sunami E., Shinozaki M., Higano C.S., et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 2009, 55:559-567.
192. Mirza S., Sharma G., Parshad R., Srivastava A., Gupta S.D., Ralhan R. Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem 2010, 43:380-386.
193. Ellinger J., Haan K., Heukamp L.C., et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008, 68:42-49.
194. Wong T.S., Kwong D.L., Sham J.S., Wei W.I., Kwong Y.L., Yuen A.P. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 2004, 10:2401-2406.
195. Bastian P.J., Palapattu G.S., Lin X., et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005, 11:4037-4043.
196. Chuang C.K., Chu D.C., Tzou R.D., Liou S.I., Chia J.H., Sun C.F. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect Prev 2007, 31:59-63.
197. Marini A., Mirmohammadsadegh A., Nambiar S., Gustrau A., Ruzicka T., Hengge U.R. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006, 126:422-431.
198. Melnikov A., Scholtens D., Godwin A., Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn 2009, 11:60-65.
199. Hoque M.O., Feng Q., Toure P., et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006, 24:4262-4269.
200. Ellinger J., El K.N., Heukamp L.C., et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol 2008, 179:346-352.
201. Leung W.K., To K.F., Man E.P., et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005, 100:2274-2279.
202. Fujiwara K., Fujimoto N., Tabata M., et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005, 11:1219-1225.
203. Hoque M.O., Begum S., Topaloglu O., et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004, 64:5511-5517.
204. Wong T.S., Man M.W., Lam A.K., Wei W.I., Kwong Y.L., Yuen A.P. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 2003, 39:1881-1887.
205. Thompson R.F., Atzmon G., Gheorghe C., et al. Tissue-specific dysregulation of DNA methylation in aging. Aging Cell 2010, 9:506-518.
206. Dominguez G., Carballido J., Silva J., et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002, 8:980-985.
207. Gifford G., Paul J., Vasey P.A., Kaye S.B., Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004, 10:4420-4426.
208. Sharma G., Mirza S., Parshad R., et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 2010, 43:373-379.
209. Hoffmann A.C., Kaifi J.T., Vallbohmer D., et al. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J Surg Oncol 2009, 100:414-417.
210. Wallner M., Herbst A., Behrens A., et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 2006, 12:7347-7352.
211. Muller H.M., Widschwendter A., Fiegl H., et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003, 63:7641-7645.
212. Mori T., O'Day S.J., Umetani N., et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005, 23:9351-9358.
213. Fischer J.R., Ohnmacht U., Rieger N., et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 2007, 56:115-123.
214. Liggett T.E., Melnikov A.A., Marks J.R., Levenson V.V. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer April 5 2010, Epub ahead of print. 10.1002/ijc.25363.
215. Toyooka S., Suzuki M., Maruyama R., et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 2004, 91:771-774.
216. Shah S.N., Hile S.E., Eckert K.A. Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypes. Cancer Res 2010, 70:431-435.
217. Coulet F., Blons H., Cabelguenne A., et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000, 60:707-711.
218. von Knobloch R., Hegele A., Brandt H., Olbert P., Heidenreich A., Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2001, 94:67-72.
219. Nakamoto D., Yamamoto N., Takagi R., Katakura A., Mizoe J.E., Shibahara T. Detection of microsatellite alterations in plasma DNA of malignant mucosal melanoma using whole genome amplification. Bull Tokyo Dent Coll 2008, 49:77-87.
220. Muller I., Beeger C., Alix-Panabieres C., Rebillard X., Pantel K., Schwarzenbach H. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin Chem 2008, 54:688-696.
221. von Knobloch R., Brandt H., Schrader A.J., Heidenreich A., Hofmann R. Molecular serological detection of DNA alterations in transitional cell carcinoma is highly sensitive and stage independent. Clin Cancer Res 2004, 10:988-993.
222. Rawnaq T., Schwarzenbach H., Schurr P.G., et al. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. J Surg Res January 27 2010, Epub ahead of print. 10.1016/j.jss.2009.12.032.
223. Schurr P.G., Oikonomou D., Kaifi J.T., et al. Clinical value of loss of heterozygosity in serum microsatellite DNA of patients with gastrointestinal stromal tumors. J Clin Gastroenterol 2009, 43:27-35.
224. Utting M., Werner W., Dahse R., Schubert J., Junker K. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res 2002, 8:35-40.
225. Sieben N.L., ter Haar N.T., Cornelisse C.J., Fleuren G.J., Cleton-Jansen A.M. PCR artifacts in LOH and MSI analysis of microdissected tumor cells. Hum Pathol 2000, 31:1414-1419.
226. Lavon I., Refael M., Zelikovitch B., Shalom E., Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 2010, 12:173-180.
227. Wang Q., Larson P.S., Schlechter B.L., et al. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer. Int J Cancer 2003, 106:923-929.
228. Fujiwara Y., Chi D.D., Wang H., et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res 1999, 59:1567-1571.
229. Fornari D., Steven K., Hansen A.B., et al. New evaluation of plasma DNA microsatellite analysis in patients with TCC of the urinary bladder. Anticancer Res 2004, 24:1733-1736.
230. von Knobloch R., Hegele A., Brandt H., et al. High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2002, 98:889-894.
231. Chen X., Bonnefoi H., Diebold-Berger S., et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999, 5:2297-2303.
232. Hickey K.P., Boyle K.P., Jepps H.M., Andrew A.C., Buxton E.J., Burns P.A. Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer 1999, 80:1803-1808.
233. Schwarzenbach H., Chun F.K., Muller I., et al. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int 2008, 102:253-258.
234. Eisenberger C.F., Stoecklein N.H., Jazra S., et al. The detection of oesophageal adenocarcinoma by serum microsatellite analysis. Eur J Surg Oncol 2006, 32:954-960.
235. Hamana K., Uzawa K., Ogawara K., et al. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer 2005, 92:2181-2184.
236. Nakayama T., Taback B., Nguyen D.H., et al. Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients. Ann NY Acad Sci 2000, 906:87-98.
237. Garcia J.M., Garcia V., Silva J., et al. Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Genes Chromosom Cancer 2006, 45:692-701.
238. Taback B., Fujiwara Y., Wang H.J., Foshag L.J., Morton D.L., Hoon D.S. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001, 61:5723-5726.
239. Lo Y.M., Chiu R.W. Next-generation sequencing of plasma/serum DNA: an emerging research and molecular diagnostic tool. Clin Chem 2009, 55:607-608.
240. Bunn P.A. Early detection of lung cancer using serum RNA or DNA markers: ready for "prime time" or for validation?. J Clin Oncol 2003, 21:3891-3893.
241. Sackett D.L., Haynes R.B. The architecture of diagnostic research. BMJ 2002, 324:539-541.